Swedish Orphan Biovitrum AB (OSTO:SOBI)
kr 276.4 3 (1.1%) Market Cap: 93.94 Bil Enterprise Value: 112.63 Bil PE Ratio: 43.61 PB Ratio: 2.63 GF Score: 87/100

Q4 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript

Feb 13, 2020 / 09:00AM GMT
Release Date Price: kr184.83 (+2.22%)
Operator

Ladies and gentlemen, welcome to the Sobi presentation of the Q4 and full year 2019 results. (Operator Instructions)

I will now hand over to Guido Oelkers, CEO. Please go ahead.

Guido Oelkers;publ;CEO;President
Swedish Orphan Biovitrum AB

()-&

Yes, good morning, everybody. It's really my pleasure to welcome you to our webcast on the Q4 results. And I think with this, we go straight into the brief. Forward-looking statement as per usual.

Today, I'm accompanied by our CFO, Henrik Stenqvist; and our Head of R&D, Milan Zdravkovic. And this has been -- 2019 has been a significant journey for the company. And before I get into the numbers, I think it's time just to quickly reflect what actually happened. We really grew now our Haemophilia business with the acquisition of Doptelet or broadened it into a Haematology franchise. We got our first launch experience with Gamifant during the year, and $56 million, I think, made our first mark. We had Synagis under -- as the first year -- in the first

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot